Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting

AIM: To describe trends of combination therapy (CT) of infliximab (IFX) and immunomodulator (IMM) for inflammatory bowel disease (IBD) in the community setting. METHODS: A retrospective study was conducted of all IBD patients referred for IFX infusion to our community infusion center between 04/01/0...

Descripción completa

Detalles Bibliográficos
Autores principales: Berkowitz, Joshua C, Stein-Fishbein, Joanna, Khan, Sundas, Furie, Richard, Sultan, Keith S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797978/
https://www.ncbi.nlm.nih.gov/pubmed/29430323
http://dx.doi.org/10.4292/wjgpt.v9.i1.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797978/
https://www.ncbi.nlm.nih.gov/pubmed/29430323
http://dx.doi.org/10.4292/wjgpt.v9.i1.8

Ejemplares similares